Basit öğe kaydını göster

dc.contributor.authorEce, Abdulilah
dc.contributor.authorBasoglu, Faika
dc.contributor.authorUlusoy-Guzeldemirci, Nuray
dc.contributor.authorAKALIN ÇİFTÇİ, GÜLŞEN
dc.contributor.authorÇETİNKAYA, SERAP
dc.date.accessioned2021-12-10T10:48:32Z
dc.date.available2021-12-10T10:48:32Z
dc.identifier.citationBasoglu F., Ulusoy-Guzeldemirci N., AKALIN ÇİFTÇİ G., ÇETİNKAYA S., Ece A., "Novel imidazo[2,1-b]thiazole-based anticancer agents as potential focal adhesion kinase inhibitors: Synthesis, in silico and in vitro evaluation", CHEMICAL BIOLOGY & DRUG DESIGN, 2021
dc.identifier.issn1747-0277
dc.identifier.othervv_1032021
dc.identifier.otherav_55aadb7c-8034-4d4e-a0a3-115895ccec5e
dc.identifier.urihttp://hdl.handle.net/20.500.12627/170621
dc.identifier.urihttps://doi.org/10.1111/cbdd.13896
dc.description.abstractThe purpose of this study was to synthesize imidazo[2,1-b]thiazole derivatives, characterize them with spectroscopical techniques and investigate for cytotoxic and apoptotic effects on glioma C6 cancer cell line. The in vitro anticancer activities were also investigated against focal adhesion kinase. Most of the compounds, particularly the derivatives carrying 3-oxo-1-tiya-4-azaspiro[4.5]decane moiety, exhibited higher or comparable activities in comparison with the reference drug, cisplatin. Compounds with methyl, propyl, phenyl moieties at the eighth and second position of the spirothiazolidinone ring showed high FAK inhibitory activities. In addition, molecular docking studies shed light on the binding modes of the synthesized compounds. The critical interactions with amino acid residues located in the active site were revealed. The results obtained from both biological assay data and computational results might provide insight into developing new inhibitors against focal adhesion kinase.
dc.language.isoeng
dc.subjectBiochemistry, Genetics and Molecular Biology (miscellaneous)
dc.subjectClinical Biochemistry
dc.subjectCancer Research
dc.subjectPharmacology
dc.subjectMolecular Biology
dc.subjectDrug Discovery
dc.subjectAging
dc.subjectGeneral Biochemistry, Genetics and Molecular Biology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectBiochemistry
dc.subjectStructural Biology
dc.subjectChemistry (miscellaneous)
dc.subjectGeneral Chemistry
dc.subjectPharmacology (medical)
dc.subjectPharmacy
dc.subjectDrug Guides
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectPhysical Sciences
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKİMYA, TIP
dc.subjectKimya
dc.subjectTemel Bilimler (SCI)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectSitogenetik
dc.subjectBiyokimya
dc.subjectTemel Bilimler
dc.titleNovel imidazo[2,1-b]thiazole-based anticancer agents as potential focal adhesion kinase inhibitors: Synthesis, in silico and in vitro evaluation
dc.typeMakale
dc.relation.journalCHEMICAL BIOLOGY & DRUG DESIGN
dc.contributor.departmentİstanbul Teknik Üniversitesi , ,
dc.contributor.firstauthorID2646013


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster